Peptide Association
Start Your Consultation
All peptides
MetabolicFDA Approved

Dulaglutide (Trulicity)

Subcutaneous injection (weekly)
Written by Peptide Association Editorial TeamMedically reviewed by Ian Justl Ellis, MD, CPTLast reviewed Editorial policy

Overview

A long-acting GLP-1 receptor agonist consisting of a GLP-1 analog covalently linked to a modified human IgG4 Fc fragment via a peptide linker. This fusion protein design increases molecular size to reduce renal clearance and enables FcRn-mediated recycling, producing a half-life of approximately 5 days suitable for once-weekly dosing.

Mechanism of Action

Dulaglutide activates pancreatic GLP-1 receptors to enhance glucose-dependent insulin secretion and suppress glucagon.

Research Summary & Key Findings

AWARD trial program demonstrated superior HbA1c reduction vs. multiple comparators. REWIND trial (2019) showed 12% reduction in MACE in type 2 diabetes patients, including those without established cardiovascular disease. FDA-approved for type 2 diabetes (2014) and cardiovascular risk reduction.

Clinical Status

FDA Approved

Dulaglutide (Trulicity) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection (weekly)

References

Primary literature

Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.

Related Peptides in Metabolic

Semaglutide (Ozempic/Wegovy)

FDA Approved

A glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...

View details

Tirzepatide (Mounjaro/Zepbound)

FDA Approved

A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...

View details

Retatrutide

In Clinical Trials

An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...

View details

AOD-9604

Investigational

A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...

View details

Start Your Consultation

Get an AI-proposed Dulaglutide (Trulicity) protocol reviewed by a physician in our network.

Start Your Consultation

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Dulaglutide (Trulicity).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.